Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Appointed director
HOOKIPA Pharma Inc. (HOOK) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Press release issued by HOOKIPA Pharma Inc. on August 10, 2023"
08/04/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
06/09/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K"
06/01/2023 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...
Docs: "UNDERWRITING AGREEMENT",
"HOOKIPA PHARMA INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A-2 CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW HOOKIPA PHARMA INC., a Delaware corporation , in accordance with the provisions of Section 103 of the Delaware General Corporation Law does hereby certify that, in accordance with Sections 141 and 151 of the DGCL, the following resolution was duly adopted by a committee of the Board of Directors of the Corporation on May 30, 2023: RESOLVED, pursuant to authority expressly set forth in the Amended and Restated Certificate of Incorporation of the Corporation , the issuance of a series of Preferred Stock designated as the Series A-2 Convertible Preferred Stock, par value $0.0001 per share, of the Corpora...",
"The New York Times Building",
"HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock NEW YORK and VIENNA, Austria, May 31, 2023 – HOOKIPA Pharma Inc. , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the pricing of an underwritten public offering of 22,900,768 shares of its common stock and 15,268 shares of its non-voting Series A-2 convertible preferred stock . The public offering price of each share of common stock is $1.31 and the public offering price of each share of non-voting Series A-2 preferred stock is $1,310.00 . The gross proceeds to HOOKIPA from this offering are expected to be approximately $50.0 million, before deducting underwriting discounts and commissions and othe..."
05/31/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "HB-200 results"
05/11/2023 8-K Quarterly results
Docs: "Press release issued by HOOKIPA Pharma Inc. on May 11, 2023"
04/13/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "HOOKIPA Pharma Inc. 2023 Inducement Plan and form of award agreements thereunder",
"HOOKIPA Pharma Inc. 2023 Inducement Plan and form of award agreements thereunder"
03/15/2023 8-K Quarterly results
Docs: "Press release issued by HOOKIPA Pharma Inc. on March 15, 2023"
03/13/2023 8-K Appointed a new director
Docs: "HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors New York, US and Vienna, Austria, March 13, 2023 - HOOKIPA Pharma Inc. , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that Terry Coelho will join its Board of Directors, Audit Committee and Compensation Committee, effective April 3, 2023. “Terry is an immensely valuable addition to our Board, given her experience in business strategy, broad financial transactions and business development, and we are thrilled to welcome her to the team,” said Joern Aldag, Chief Executive Officer at HOOKIPA. “Terry has worked with companies large and small and navigated fast-paced, complex business environments, including in the pharmaceutical sector. We will undoubtedly bene..."
01/20/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "FORM 8-K"
12/15/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
10/20/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/06/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/02/2022 8-K Quarterly results
04/20/2022 8-K Appointed a new director
Docs: "HOOKIPA Pharma Appoints Tim Reilly, Ph.D. to its Board of Directors New York, US and Vienna, Austria, April 20, 2022 - HOOKIPA Pharma Inc. , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Tim Reilly, Ph.D. to its Board of Directors, effective immediately. “We’ re pleased to have Tim join our Board as we advance our oncology pipeline of novel arenaviral immunotherapeutics in and towards the clinic,” said Joern Aldag, Chief Executive Officer at HOOKIPA. “Tim’ s experience in product development, especially driving early clinical development that supports eventual marketed products, is enormously relevant to our current focus. We will benefit from his insights on our ongoing Phase 2 HB-200 program for hea..."
03/24/2022 8-K Quarterly results
Docs: "Press release issued by HOOKIPA Pharma Inc. on March 24, 2022"
03/03/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
02/15/2022 8-K Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T...
Docs: "Stock Purchase Agreement, by and between HOOKIPA Pharma Inc. and Gilead Sciences, Inc",
"HOOKIPA and Gilead Amend Collaboration and License Agreement to Develop Immunotherapies Against HIV · HOOKIPA to develop arenaviral-based therapeutic for HIV through Phase 1b clinical trial completion; Gilead has exclusive rights for further program development thereafter · Financial terms include $15 million initiation fee and $35 million equity commitment New York City, US and Vienna, Austria, February 15, 2022 - HOOKIPA Pharma Inc. , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced it has entered into an amended and restated collaboration and license agreement with Gilead to advance the development of a novel arenaviral immunotherapy as a component of a potential functional curative regimen for human immun..."
02/01/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K"
11/10/2021 8-K Quarterly results
Docs: "Press release issued by HOOKIPA Pharma Inc. on November 10, 2021"
11/09/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "HB-200 data update"
08/12/2021 8-K Quarterly results
Docs: "Press release issued by HOOKIPA Pharma Inc. on August 12, 2021"
06/07/2021 8-K Quarterly results
05/12/2021 8-K Quarterly results
04/19/2021 8-K Quarterly results
03/18/2021 8-K Quarterly results
12/11/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Series A Certificate of Designation"
12/07/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "About the trial This Phase 1/2 clinical trial is an open-label dose-escalation and dose-expansion trial in individuals with treatment-refractory HPV16 + cancers. The primary endpoint of the Phase 1 trial is a recommended Phase 2 dose based on safety and tolerability. Secondary endpoints include anti-tumor activity as defined by RECIST 1.1, immunogenicity, safety, and tolerability. The trial is designed to evaluate different dose levels of HB-201 as a single-vector therapy, as an alternating two-vector therapy together with HB-202, and in combination with a PD-1 inhibitor. Dosing frequencies of every three weeks and every two weeks are being explored during dose escalation. Since the trial opened in December 2019, 22 patients with metastatic HPV16 + tumors have been enrolled in the HB-201 m...",
"HOOKIPA Pharma Inc. Investor Presentation"
11/30/2020 8-K Investor presentation
Docs: "HOOKIPA Announces Positive Phase 2 Interim Safety, Immunogenicity, and Efficacy Data for its Cytomegalovirus Vaccine Candidate HB-101",
"HOOKIPA Pharma Inc. Investor Presentation"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy